Astrazeneca Receives Japan Approval for CFC-free Corticosteroid Inhaler for Paediatric Asthma.

Tokyo, Japan, Aug 3, 2006 - (JCN) - Astrazeneca announced on July 27 that it had received approval for its Pulmicort Turbuhaler, an inhaler for pediatric asthma infants from 6 months to under 5 years old, frrom the Japanese Ministry of Health, Labor and Welfare.

Pulmicort Turbuhaler is taken once daily with an electronic nebuliser that change liquid medicines into a fine mist for easy breathing in. The three main efficiency of the drug include reduced inflammation in the airways of lungs, reduced asthma attack frequency by 50% for 2 weeks use and as much as 75% during a 12 week period, and reduced sleep distraction of 61.4%.

The drug has been recommended in the guidelines for Management of treatment for Pediatric Patients of Bronchial Asthma, set forth by the Japanese Society of Pediatric Allergy and Clinical Immunology.

AstraZeneca expect rapid use of the medication.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.